ABSTRACT
PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized. PATIENTS AND METHODS: Nine clinical trials of metastatic cancer were included in this analysis. Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491). Patients not treated with lapatinib comprised the control group. Dermatologic events included hand-foot syndrome, rash, hair disorder, dry skin, pruritus/urticaria, skin disorder, skin infection, and nail disorder; DEs were characterized based on type, time to onset, severity, duration, and required interventions. RESULTS: Fifty-eight percent of patients treated with lapatinib monotherapy, 74% treated with lapatinib plus paclitaxel or capecitabine, and 53% in the control group developed DEs. Among patients receiving lapatinib monotherapy, 55% experienced grade 1/2 DEs, 3% had grade 3 DEs, and no grade 4 DEs were observed. The most common DE was rash (43%); all other events occurred in Subject(s)
Neoplasms/drug therapy
, Quinazolines/administration & dosage
, Quinazolines/adverse effects
, Skin Diseases/etiology
, Adult
, Aged
, Aged, 80 and over
, Antineoplastic Combined Chemotherapy Protocols/administration & dosage
, Antineoplastic Combined Chemotherapy Protocols/adverse effects
, Capecitabine
, Clinical Trials as Topic
, Deoxycytidine/administration & dosage
, Deoxycytidine/analogs & derivatives
, Dose-Response Relationship, Drug
, ErbB Receptors/metabolism
, Exanthema/etiology
, Female
, Fluorouracil/administration & dosage
, Fluorouracil/analogs & derivatives
, Humans
, Lapatinib
, Male
, Middle Aged
, Neoplasms/complications
, Paclitaxel/administration & dosage
, Treatment Outcome